aibioTracker
Biotech winners and losers
The biotech stocks with the biggest reported moves, up and down, and the news behind each one: takeovers, trial results, IPO debuts and financings.
Biggest gainers
| Date | Company | Move | Why |
|---|---|---|---|
| Oct 19 | Silence Therapeutics | +130% | Merck KGaA offers $20 per ADS in cash, a 130% premium to the Oct. 16 close. Our story |
| Oct 16 | City Therapeutics | +28% | Opened at $23 on its Nasdaq debut after an upsized $200 million IPO priced at $18. Our story |
| Oct 20 | Disc Medicine | $450M | Upsized raise at $75 a share, one day after a positive phase 3 result. Our story |
| Oct 9 | Vaxcyte | $1.1B | Raised about $1.1 billion at $64 a share and a 1.50% convertible, after a phase 3 win. Our story |
| Sep 24 | Viking Therapeutics | +45% | Sold $259 million of 2% converts at a 45% conversion premium, plus stock at $35, after maintenance data. Our story |
| Aktis Oncology | IPO upsized, raises about $318M at $18 Our story | ||
| Alumis | Raises $300M after psoriasis pill wins phase 3 Our story | ||
| Monte Rosa Therapeutics | Upsizes stock sale to $300M after NEK7 data Our story | ||
| United Therapeutics | Authorizes another $2B share buyback Our story | ||
| Ultragenyx | Sells two priority review vouchers for $413M Our story | ||
| Protagonist Therapeutics | $300M buyback after two drug approvals Our story | ||
| Celldex Therapeutics | Closes $345M raise, funded through 2028 Our story |
Biggest losers
| Date | Company | Move | Why |
|---|---|---|---|
| Oct 19 | EyePoint | -80% | Shares fell more than 80% at the open to 55 cents after a second Duravyu wet AMD phase 3 miss. Our story |
| Oct 16 | Fractyl Health | -48% | Shares fell about 48% to around $2.14 even though Revita met its six-month endpoint. Our story |
| Aug 31 | BioAtla | OTC | Nasdaq upheld its delisting. Trading moved from Nasdaq to the OTC Markets under BCAB on Aug. 31. SEC Form 8-K |
| Sep 19 | Xenon | -26% | Shares fell 26% pre-market to $42.25 from $57.35 after it paused phase 3 depression enrollment. Our story |
| Oct 21 | Arcus Biosciences | -8% | Raised $250 million at $17.50, about 8% below the last sale, after the stock fell about 20% in two days. Our story |
| BioXcel Therapeutics | Files Chapter 11, Teva is stalking horse Our story | ||
| TScan Therapeutics | Cuts 75% of staff, pauses phase 3 Our story | ||
| Lisata Therapeutics | Cuts 72% of staff after failed buyout Our story | ||
| Sangamo Therapeutics | Nasdaq delisting final in Chapter 11 Our story | ||
| Senti Biosciences | Two Nasdaq notices: bid price and equity Our story | ||
| Capricor Therapeutics | New class action and derivative suit Our story | ||
| Outlook Therapeutics | Nasdaq bid-price notice after approval Our story |